Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.

Abstract

Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent. Ticlopidine caused significant inhibition of platelet aggregation but did not fully correct abnormalities of coagulation, viscosity, and fibrinolysis. There was no significant improvement in walking ability, Doppler ankle-pressure indices, or calf blood flow. Sustained platelet inhibition for 12 months was insufficient to correct the prothrombotic abnormality of extensive atherosclerosis.

• Authors: A Aukland, R A Hurlow, A J George, J Stuart
• Journal: Journal of clinical pathology (J Clin Pathol) Vol. 35 Issue 7 Pg. 740-3 (Jul 1982) ISSN: 0021-9746 [Print] England
• PMID: 7047575 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Thiophenes
• Ticlopidine

Topics

• Adult
• Aged
• Arteriosclerosis (complications)
• Clinical Trials as Topic
• Double-Blind Method
• Humans
• Intermittent Claudication (drug therapy, etiology)
• Male
• Middle Aged
• Platelet Aggregation (drug effects)
• Random Allocation
• Thiophenes (therapeutic use)
• Ticlopidine